Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610831 | 0.86 | ROCK2 (0.42) | ROCK2RIPK1CCNCCDK8HTT | |
| SCHEMBL14557703 | 0.83 | ROCK2 (0.40) | ROCK2RIPK1CCNCCDK8 | |
| SCHEMBL17454944 | 0.75 | RIPK1 (0.69) | RIPK1CCNCCDK8HTTPOLB | |
| SCHEMBL8275419 | 0.75 | RIPK1 (0.69) | RIPK1CCNCCDK8HTTPOLB | |
| SCHEMBL11510126 | 0.74 | RIPK1 (0.56) | RIPK1HSD17B10POLBHSP90AA1HSP90AB1 | |
| SCHEMBL17454945 | 0.73 | CCNC (0.52) | ROCK2RIPK1CCNCCDK8HSD17B10 | |
| SCHEMBL29515757 | 0.73 | RIPK1 (0.50) | RIPK1CCNCCDK8ACHEHSD17B10 | |
| SCHEMBL17454943 | 0.73 | HSD11B1 (0.54) | ROCK2RIPK1CCNCCDK8SMN1; SMN2 | |
| SCHEMBL1423483 | 0.73 | RIPK1 (0.50) | RIPK1CCNCCDK8ACHEHSD17B10 | |
| SCHEMBL13300490 | 0.73 | RIPK1 (0.50) | RIPK1CCNCCDK8ACHEHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ROCK2 1291/4885RIPK1 4081/4885CCNC 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.